Table 1.

Summary of paclitaxel/navitoclax combinations in 27 ovarian cancer cell lines

Cell lineAverage Bliss sumSD Bliss sumAverage combined% inhibitionaSD combined % inhibitionaAverage % inhibition (100 nmol/L paclitaxel)SD % inhibition (100 nmol/L paclitaxel)Average % inhibition (3 μmol/L navitoclax)SD % inhibition (3 μmol/L navitoclax)Paclitaxel IC50 (nmol/L)SD paclitaxel IC50Navitoclax IC50 (μmol/L)SD navitoclax IC50 (μmol/L)
CA-OV31,186403688.62010.71114.9NANA
IGROV1567343924.2634.84718.696.4NA
59M552354683.1269.6144.3NANA
OV56542139730.1327.8244.1NANA
Fu-Ov-1535235873.3422.1254.8NANA
OV9052640904.1483.05111.4NANA
Ovcar451588921.7624.3177.4104.8NA
Dor1346199922.2578.36911.14652.60.50.1
ES2-TO340207913.4574.9224.14219.5NA
Ovcar831519990.4902.11711.551.6NA
EFO2725169913.17311.04812.263.2NA
Ovcar527323970.7832.74812.240.9NA
SKOV326899943.5773.0559.261.31.00.3
OvCA420268938116.45017.25621.5NANA
OvCA429246217818.16511.783.976.2NA
OvCA4332281657120.26317.01212.61918.4NA
TOV112D22719932.6836.35705.330.71.30.4
Ovcar31611117527.35333.8307.4NANA
OvCA432159658019.54814.84715.3NANA
A2780122187960.5814.9156.421.2NA
A2780ADR120128373.6243.4165.6NANA
HEY1110191866.25711.72311.41821.3NA
OAW288093902.2656.1872.751.50.040.01
TOV21G75109734.2628.1251.91620.9NA
OAW4248105864.9594.5812.72112.90.70.2
COLO704−86176718.8516.13720.0NANA

NOTE: Navitoclax was dosed in a range of 3 μmol/L to 10 nmol/L in 7 threefold dilutions, and paclitaxel was dosed in the range of 100 nmol/L to 10 pmol/L in 9 threefold dilutions. Each value reported is the average of at least 3 independent experiments run in quadruplicate. IC50 values and Bliss scores were measured using CellTiter-Glo.

a% Inhibition at 100 nmol/L paclitaxel and 3 μmol/L navitoclax.